Effect of Amnio-Maxx on the Healing Rate of Chronic Diabetic Foot Ulcers.
A legfontosabb adatok
- Ki végzi
- Royal Biologics
- Hol
- Burbank, Carrollton, East Patchogue, Miami, Omaha, Spicewood, Stone Mountain és Tulsa (Egyesült Államok)Mind a 8 helyszín megnézése
- Azonosító
- Állapot
- Toboroz
- Fázis
- 4. fázis
- Résztvevők
- 248 fő, tervezett
- Kezdés
- 2025. aug. 14.
- Tervezett befejezés
- 2026. aug. 14.
- A vizsgálat típusa
- Beavatkozással járó, 2 csoport
- A vizsgált kezelések
- Amnio-Maxx® Dual Layer Amnion Patch
- Standard of Care (Investigator Choice)
- A regiszteradat frissítve
- 2025. október 7.
Ki vehet részt
MI-összefoglaló
A vizsgálat saját részvételi feltételeiből. Gép olvasta ki az oldalon álló regiszterszövegből, ezért tévedhet. Hogy ki vehet részt, azt a lenti regiszterszöveg és a vizsgálat csapata dönti el.
The trial is looking for adults with type 1 or type 2 diabetes who have a foot ulcer that is not healing. It compares the Amnio-Maxx® Dual Layer Amnion Patch plus standard care with standard care alone.
- Életkor
- 18 years or older. At least 50% of people in the trial must be over 65 years.
- Nem
- All sexes can join.
- A betegség stádiuma
- A diabetic foot ulcer of Wagner grade 1 or 2, at or below the inner ankle bone. It has been present for more than 4 weeks but less than 12 months. It measures 1.0 cm2 to 25 cm2 after cleaning. It healed less than 20% during the 2-week screening period. Blood flow to the foot must be good enough on a test. The ulcer base must be clean, without dead tissue. Any past infection must be treated and under control.
- Korábbi kezelés
- Diabetes must be treated with tablets and/or insulin. The ulcer must have been off-loaded with the trial's pressure-relief device for at least 14 days before the start. No tissue-engineered or scaffold products on the ulcer in the last 30 days. No immunosuppressants, steroids over 10mg a day, chemotherapy or steroid creams on the ulcer within 30 days before the start.
A részvétel fő kizáró okai
- Expected to live less than 1 year.
- Ulcer shrank by 20% or more during the 2 weeks of screening.
- Major uncontrolled illness, such as serious heart, kidney, liver or lung disease, lupus or sickle cell anemia, or palliative care.
- Being treated for active cancer, or past cancer in the ulcer.
- Pregnant or breastfeeding, or allergic to amniotic tissue or Amnio-Maxx parts.
A regiszter feltételei, szó szerint
Mind a 29 feltétel megnézéseKevesebb
Ki vehet részt
- Potential subjects are required to meet all the following criteria for enrollment into the study and subsequent randomization
- The potential subject is 18 years of age or older. At least 50% of the enrolled population must be > 65 years of age
- The potential subject has a history of Type I or Type II Diabetes Mellitus requiring treatment by a physician with either oral medications and/or insulin replacement therapy
- Potential subjects have an ulcer characterized by the following:; Presence of a diabetic foot ulcer Wagner 1 or 2 grade at the first screening visit on any aspect of the foot, provided it is at or below the aspect of the medial malleolus. [NOTE: If two or more DFUs are present with the same grade, the index ulcer is the largest ulcer and the only one evaluated in the study. Index ulcer must be more than 5 cm distant apart.]; A diabetic foot ulcer present for greater than 4 weeks (documented in the medical record) but less than 12 months duration if being treated with active SOC
- Objectively, less than 20% healing in the two-week screening period prior to randomization
- Study ulcer is a minimum of 1.0cm2 and a maximum of 25 cm2 post-debridement at first treatment visit
- Index ulcer and/or index ulcer limb may have had prior infection, but infection(s) must be adequately treated and controlled as defined by IDSA Guidelines Grade level 1
- The subject is able and willing to follow the protocol requirements
- Subject has signed informed consent. Adequate circulation to the affected foot as demonstrated by a dorsum transcutaneous oxygen measurement (TCOM) or a skin perfusion pressure (SPP) measurement of ≥ 30 mmHg; an ABI between 0.7 and ≤ 1.3, or TBI of >6 within 3 months of the first Screening Visit
- Negative pregnancy test for females of childbearing potential (e.g., not post- menopausal for at least one year or surgically sterile). Females of childbearing potential must be willing to use acceptable methods of contraception (birth control methods, barriers, or abstinence) starting at Screening and continuing through the duration of their study participation
- The index ulcer has been offloaded with protocol defined offloading device throughout the study run-in period for at least 14 days prior to randomization (Run-in period defined as Screening through TV1/Randomization)
- The index ulcer has a clean base and is free of necrotic debris at time of placement of treatment product
Ki nem vehet részt
- The Subject has other concurrent conditions that in the opinion of the Principal Investigator may compromise subject safety
- Concurrent participation in another clinical trial that involves an investigational drug or device that would interfere with this study
- Subjects with a history of more than two weeks treatment with immunosuppressants (including systemic corticosteroids
- >10mg daily dose), cytotoxic chemotherapy, or application of topical steroids to the ulcer surface within 30 days prior to randomization visit or who receive such medications during the screening period, or who are anticipated to require such medications during the course of the study
- Index ulcer has been previously treated with tissue engineered materials (e.g. Apligraf® or Dermagraft®) or other scaffold materials (e.g. Oasis, Matristem) within the last 30 days preceding the first treatment visit; -
- Index ulcer has been present for >1 year
- Presence of any condition(s) which seriously compromises the subject's ability to complete this study or has a known history of poor adherence to medical treatment
- Subject has major uncontrolled medical disorders such as serious cardiovascular, renal, liver or pulmonary disease, lupus, palliative care or sickle cell anemia
- Subject currently being treated for an active malignant disease
- or subjects with history of malignancy within the ulcer
- Known contraindications to amniotic tissue membranes or known allergies to any of the Amnio-Maxx components
- Index ulcer has reduced in area by 20% or more after 2 weeks of standard of care from the first screening visit (S1) to the TV1/randomization visit
- The Subject has a known life expectancy of < 1 year
- Patient does not have adequate 2-week historical data demonstrating < 20% area reduction
- Subject is unable to comply with offloading device
- Subject has ulcers that are completely necrotic or fibrotic tissue
- Subject is pregnant or breastfeeding
Ez a vizsgálat jelenleg itt érhető el: Egyesült Államok.
- Lion Heart Clinical ResearchBurbank, Egyesült ÁllamokContact: Nicole SchrecngostRésztvevőt keres
- VAST Clinical Research Carrollton Foot CenterCarrollton, Egyesült ÁllamokContact: Nicole SchrecngostRésztvevőt keres
- Suffolk Foot and AnkleEast Patchogue, Egyesült ÁllamokContact: Nicole SchrecngostRésztvevőt keres
- Royal Research SouthMiami, Egyesült ÁllamokContact: Nicole SchrecngostRésztvevőt keres
- SerenaGroup Research CenterOmaha, Egyesült ÁllamokContact: Nicole SchrecngostRésztvevőt keres
- Elite Foot & Ankle AssociatesSpicewood, Egyesült ÁllamokContact: Nicole SchrecngostRésztvevőt keres
- Denali Health Atlanta, LLCStone Mountain, Egyesült ÁllamokContact: Nicole SchrecngostRésztvevőt keres
- Wound Care of TulsaTulsa, Egyesült ÁllamokContact: Nicole SchrecngostRésztvevőt keres
A vizsgálatról
Mit akar kideríteni a vizsgálat
This study will evaluate a cellular, acellular, matrix-like product (CAMP) and Standard of Care (SOC) versus SOC alone in the closure of nonhealing diabetic foot ulcers (DFUs). The study will evaluate Amnio-Maxx® Dual Layer Amnion Patch.
A vizsgálat 2 csoportja
- Standard of CareA vizsgált kezelés
Cleansing, debridement, wound documentation, off-loading
Kezelés: Standard of Care (Investigator Choice)
- Amnio-Maxx® Dual Layer Amnion PatchA vizsgált kezelés
Application of Amnio-Maxx® Dual Layer Amnion Patch
Kezelés: Amnio-Maxx® Dual Layer Amnion Patch és Standard of Care (Investigator Choice)
Kérdések a vizsgálat csapatának
- Milyen gyakran kell bejárnom, és egy-egy alkalom mennyi ideig tart?
- Megtérítik az utazási költséget?
- Megtarthatom a saját orvosomat?
- Mi történik, ha ki akarok lépni?
Contact the study team: see the registry record → Contacts and Locations
Oldal nyomtatása az orvosomnakAdatok és források
- Regiszteradat
- Szerepel a ClinicalTrials.gov-on.
- Hivatalos cím
- A Randomized Controlled Multicenter Trial, Examining the Effect of Amnio-Maxx on the Healing Rate of Chronic Diabetic Foot Ulcers.
- MI-összefoglaló
- A vizsgálat saját részvételi feltételeiből. Gépi kiolvasás: 2026. november 15.
- A regiszteradat frissítve
- 2025. október 7.